



(51) International Patent Classification:

A61K 31/137 (2006.01) A61P 25/08 (2006.01)
A61K 31/235 (2006.01)

(21) International Application Number:

PCT/US2019/043765

(22) International Filing Date:

26 July 2019 (26.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/711,051 27 July 2018 (27.07.2018) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 200 - 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).(72) Inventors: **BECHARD, Jeffrey Paul**; 3445 148A Street, Surrey, British Columbia V4P 0B9 (CA). **SHERRINGTON, Robin Paul**; 111-13th Street East, Apartment #605, North Vancouver, British Columbia V7N 2L3 (CA). **CADIEUX, Jean-Jacques Alexandre**; 58-9229 University Crescent, Burnaby, British Columbia V5A 4Z2 (CA). **TARI, Parisa Karimi**; 312-3788 West 8th Avenue, Vancouver, British Columbia V6R 1Z3 (CA).(74) Agent: **ROSENMAN, Stephen J.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHOD FOR TREATING EPILEPSY




FIG. 1

(57) Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*